Lung adenocarcinoma (LUAD) is a significant planetary health challenge with its high morbidity and mortality rate, not to mention the marked interindividual variability in treatment outcomes and side effects. There is an urgent need for robust systems biomarkers that can help with early cancer diagnosis, prediction of treatment outcomes, and design of precision/personalized medicines for LUAD. The present study aimed at systems biomarkers of LUAD and deployed integrative bioinformatics and machine learning tools to harness gene expression data. Predictive models were developed to stratify patients based on prognostic outcomes. Importantly, we report here several potential key genes, for example, PMEL and BRIP1, and pathways implicated in the progression and prognosis of LUAD that could potentially be targeted for precision/personalized medicine in the future. Our drug repurposing analysis and molecular docking simulations suggested eight drug candidates for LUAD such as heat shock protein 90 inhibitors, cardiac glycosides, an antipsychotic agent (trifluoperazine), and a calcium ionophore (ionomycin). In summary, this study identifies several promising leads on systems biomarkers and drug candidates for LUAD. The findings also attest to the importance of integrative bioinformatics, structural biology and machine learning techniques in biomarker discovery, and precision oncology research and development.
Get full access to this article
View all access options for this article.
References
1.
AliM, DelozierCD, ChaudharyU. BRIP-1 germline mutation and its role in colon cancer: Presentation of two case reports and review of literature. BMC Med Genet, 2019; 20(1):75; doi: 10.1186/s12881-019-0812-0
2.
AnN, SunY, MaL, et al.Helveticoside exhibited p53-dependent anticancer activity against colorectal cancer. Arch Med Res, 2020; 51(3):224–232; doi: 10.1016/j.arcmed.2020.02.007
3.
AndriniE, MoscaM, GalvaniL, et al.Non-small-cell lung cancer: How to manage RET-positive disease. Drugs Context, 2022; 11:1–12; doi: 10.7573/dic.2022-1-5
4.
AshburnerM, BallCA, BlakeJA, et al.Gene ontology: Tool for the unification of biology. Nat Genet, 2000; 25(1):25–29; doi: 10.1038/75556
5.
BarrettT, TroupDB, WilhiteSE, et al.NCBI GEO: Mining tens of millions of expression profiles - database and tools update. Nucleic Acids Res, 2007; 35(Database Issue):D760–D765; doi: 10.1093/nar/gkl887
6.
BermanHM, WestbrookJ, FengZ, et al.The protein data bank. Nucleic Acids Res, 2000; 28(1):235–242; doi: 10.1093/nar/28.1.235
BiH, RenD, DingX, et al.Clinical characteristics of patients with ROS1 gene rearrangement in non-small cell lung cancer: A meta-analysis. Transl Cancer Res, 2020; 9(7):4383–4392; doi: 10.21037/tcr-20-1813
BudisanL, ZanoagaO, BraicuC, et al.Links between infections, lung cancer, and the immune system. Int J Mol Sci, 2021; 22(17):9394; doi: 10.3390/ijms22179394
11.
ChengY, YangX, WangY, et al.Multiple machine-learning tools identifying prognostic biomarkers for acute myeloid leukemia. BMC Med Inform Decis Mak, 2024; 24(1):2; doi: 10.1186/s12911-023-02408-9
12.
CongY, EndoT. Multi-omics and artificial intelligence-guided drug repositioning: Prospects, challenges, and lessons learned from COVID-19. Omics, 2022; 26(7):361–371; doi: 10.1089/omi.2022.0068
13.
CoxAD, FesikSW, KimmelmanAC, et al.Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov, 2014; 13(11):828–851; doi: 10.1038/nrd4389
14.
de BruijnI, KundraR, MastrogiacomoB, et al.Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in CBioPortal. Cancer Res, 2023; 83(23):3861–3867; doi: 10.1158/0008-5472.CAN-23-0816
15.
De MeesC, BakkerJ, SzpirerJ, et al.Alpha-fetoprotein: From a diagnostic biomarker to a key role in female fertility. Biomark Insights, 2007; 1(1):117727190600100–117727190600185; doi: 10.1177/117727190600100002
16.
DengC, ZhangY, MaZ, et al.Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma. J Thorac Cardiovasc Surg, 2021; 162(3):664–674.e7; doi: 10.1016/j.jtcvs.2020.05.099
17.
DerbalY. Perspective on the dynamics of cancer. Theor Biol Med Model, 2017; 14(1):18; doi: 10.1186/s12976-017-0066-5
18.
EngelmanJA, ZejnullahuK, MitsudomiT, et al.MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 2007; 316(5827):1039–1043; doi: 10.1126/science.1141478
19.
FaragoAF, TaylorMS, DoebeleRC, et al.Clinicopathologic features of non–small-cell lung cancer harboring an NTRK gene fusion. JCO Precis Oncol, 2018; 2018(2):1–12; doi: 10.1200/PO.18.00037
20.
Felippe Gonçalves-de-AlbuquerqueC, Ribeiro SilvaA, Ignácio da SilvaC, et al.Na/K Pump and beyond: Na/K-ATPase as a modulator of apoptosis and autophagy. Molecules, 2017; 22(4):578; doi: 10.3390/molecules22040578
21.
FriedmanJ, HastieT, TibshiraniR. Regularization paths for generalized linear models via coordinate descent. J Stat Softw, 2010; 33(1):1–22; doi: 10.18637/jss.v033.i01
22.
GaoL, LiG-S, LiJ-D, et al.Identification of the susceptibility genes for COVID-19 in lung adenocarcinoma with global data and biological computation methods. Comput Struct Biotechnol J, 2021; 19:6229–6239; doi: 10.1016/j.csbj.2021.11.026
23.
GendarmeS, BylickiO, ChouaidC, et al.ROS-1 fusions in non-small-cell lung cancer: Evidence to date. Curr Oncol, 2022; 29(2):641–658; doi: 10.3390/curroncol29020057
24.
GoksulukD, ZararsizG, KorkmazS, et al.MLSeq: Machine learning interface for RNA-sequencing data. Comput Methods Programs Biomed, 2019; 175:223–231; doi: 10.1016/j.cmpb.2019.04.007
25.
GrossmanK, BeasleyMB, BramanSS. Hepatoid adenocarcinoma of the lung: Review of a rare form of lung cancer. Respir Med, 2016; 119:175–179; doi: 10.1016/j.rmed.2016.09.003
26.
GuaitoliG, ZulloL, TiseoM, et al.Non-small-cell lung cancer: How to manage BRAF-mutated disease. Drugs Context, 2023; 12:1–19; doi: 10.7573/dic.2022-11-3
27.
HanS, TieX, MengL, et al.PMA and ionomycin induce glioblastoma cell death: Activation-induced cell-death-like phenomena occur in glioma cells. PLoS One, 2013; 8(10):e76717; doi: 10.1371/journal.pone.0076717
28.
HochmairM, RathB, KlamethL, et al.Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines. Invest New Drugs, 2020; 38(4):946–955; doi: 10.1007/s10637-019-00847-8
29.
HsuJB, ChangTH, LeeGA, et al.Identification of potential biomarkers related to glioma survival by gene expression profile analysis. BMC Med Genomics, 2019; 11(Suppl 7):34; doi: 10.1186/s12920-019-0479-6
30.
IrwinJJ, TangKG, YoungJ, et al.ZINC20—A free ultralarge-scale chemical database for ligand discovery. J Chem Inf Model, 2020; 60(12):6065–6073; doi: 10.1021/acs.jcim.0c00675
IslamR, AhmedL, PaulBK, et al.Identification of molecular biomarkers and pathways of NSCLC: Insights from a systems biomedicine perspective. J Genet Eng Biotechnol, 2021; 19(1):43; doi: 10.1186/s43141-021-00134-1
33.
JeongJY, ParkH, YooH, et al.Trifluoperazine and its analog suppressed the tumorigenicity of non-small cell lung cancer cell; Applicability of antipsychotic drugs to lung cancer treatment. Biomedicines, 2022; 10(5):1046; doi: 10.3390/biomedicines10051046
34.
JiY, LinZ, LiG, et al.Identification and validation of novel biomarkers associated with immune infiltration for the diagnosis of osteosarcoma based on machine learning. Front Genet, 2023; 14:1136783; doi: 10.3389/fgene.2023.1136783
35.
KamalL, PierceSB, CanavatiC, et al.Helicase-inactivating BRIP1 mutation yields fanconi anemia with microcephaly and other congenital abnormalities. Cold Spring Harb Mol Case Stud, 2020; 6(5):a005652; doi: 10.1101/mcs.a005652
36.
KamburovA, PentchevK, GalickaH, et al.ConsensusPathDB: Toward a more complete picture of cell biology. Nucleic Acids Res, 2011; 39(Database Issue):D712–D717; doi: 10.1093/nar/gkq1156
37.
KanehisaM, GotoS. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res, 2000; 28(1):27–30; doi: 10.1093/nar/28.1.27
38.
KatheejaMN, DasSP, DasR, et al.BRCA1 interactors, RAD50 and BRIP1, as prognostic markers for triple-negative breast cancer severity. Front Genet, 2023; 14:1035052; doi: 10.3389/fgene.2023.1035052
39.
KaushikV, YakisichJ, KumarA, et al.Ionophores: Potential use as anticancer drugs and chemosensitizers. Cancers (Basel), 2018; 10(10):360; doi: 10.3390/cancers10100360
40.
KegerreisB, CatalinaMD, BachaliP, et al.Machine learning approaches to predict lupus disease activity from gene expression data. Sci Rep, 2019; 9(1):9617; doi: 10.1038/s41598-019-45989-0
41.
KhalsanM, MachadoLR, Al-ShameryES, et al.A survey of machine learning approaches applied to gene expression analysis for cancer prediction. IEEE Access, 2022; 10:27522–27534; doi: 10.1109/ACCESS.2022.3146312
42.
KhanU, KhanMS. Prognostic value estimation of BRIP1 in breast cancer by exploiting transcriptomics data through bioinformatics approaches. Bioinform Biol Insights, 2021; 15:11779322211055892; doi: 10.1177/11779322211055892
43.
KiraK, RendellLA. A practical approach to feature selection. In: Machine Learning Proceedings. (SleemanD, EdwardsP. eds.) Elsevier, 1992; pp. 249–256; doi: 10.1016/B978-1-55860-247-2.50037-1
44.
KononenkoI, ŠimecE, Robnik-ŠikonjaM. Overcoming the myopia of inductive learning algorithms with RELIEFF. Applied Intelligence, 1997; 7(1):39–55; doi: 10.1023/A:1008280620621
45.
LeiterA, VeluswamyRR, WisniveskyJP. The global burden of lung cancer: Current status and future trends. Nat Rev Clin Oncol, 2023; 20(9):624–639; doi: 10.1038/s41571-023-00798-3
46.
LeonardiGC, AccardiG, MonasteroR, et al.Ageing: From inflammation to cancer. Immun Ageing, 2018; 15:1; doi: 10.1186/s12979-017-0112-5
47.
LiZN, LuoY. HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review). Oncol Rep, 2023; 49(1):6; doi: 10.3892/or.2022.8443
48.
LiMX, SunXM, ChengWG, et al.Using a machine learning approach to identify key prognostic molecules for esophageal squamous cell carcinoma. BMC Cancer, 2021; 21(1):906; doi: 10.1186/s12885-021-08647-1
49.
LibbrechtMW, NobleWS. Machine learning applications in genetics and genomics. Nat Rev Genet, 2015; 16(6):321–332; doi: 10.1038/nrg3920
50.
LinJJ, RitterhouseLL, AliSM, et al.ROS1 fusions rarely overlap with other oncogenic drivers in non–small cell lung cancer. J Thorac Oncol, 2017; 12(5):872–877; doi: 10.1016/j.jtho.2017.01.004
51.
LongG, HuK, ZhangX, et al.Spectrum of BRCA1 interacting helicase 1 aberrations and potential prognostic and therapeutic implication: A pan cancer analysis. Sci Rep, 2023; 13(1):4435; doi: 10.1038/s41598-023-31109-6
52.
LoveMI, HuberW, AndersS. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol, 2014; 15(12):550; doi: 10.1186/s13059-014-0550-8
53.
LuD, ChoiMY, YuJ, et al.Salinomycin inhibits wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A, 2011; 108(32):13253–13257; doi: 10.1073/pnas.1110431108
54.
MaPC, JagadeeswaranR, JagadeeshS, et al.Functional expression and mutations of C-met and its therapeutic inhibition with SU11274 and small interfering RNA in non–small cell lung cancer. Cancer Res, 2005; 65(4):1479–1488; doi: 10.1158/0008-5472.CAN-04-2650
55.
MäbertK, CojocM, PeitzschC, et al.Cancer biomarker discovery: Current status and future perspectives. Int J Radiat Biol, 2014; 90(8):659–677; doi: 10.3109/09553002.2014.892229
56.
MajeedU, ManochakianR, ZhaoY, et al.Targeted therapy in advanced non-small cell lung cancer: Current advances and future trends. J Hematol Oncol, 2021; 14(1):108; doi: 10.1186/s13045-021-01121-2
57.
MaroniG, BassalMA, KrishnanI, et al.Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer. Commun Biol, 2021; 4(1):370; doi: 10.1038/s42003-021-01897-6
58.
Martín-MoralesL, GarreP, LorcaV, et al.BRIP1, a gene potentially implicated in familial colorectal cancer type X. Cancer Prev Res (Phila), 2021; 14(2):185–194; doi: 10.1158/1940-6207.CAPR-20-0316
59.
MiyakeH, HaraI, YamanakaK, et al.Calcium ionophore, ionomycin inhibits growth of human bladder cancer cells both in vitro and in vivo with alteration of Bcl-2 and Bax expression levels. J Urol, 1999; 162(3 Pt 1):916–921; doi: 10.1097/00005392-199909010-00090
60.
MorrisGM, HueyR, LindstromW, et al.AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem, 2009; 30(16):2785–2791; doi: 10.1002/jcc.21256
61.
NiuM, ZhangB, LiL, et al.Targeting HSP90 inhibits proliferation and induces apoptosis through AKT1/ERK pathway in lung cancer. Front Pharmacol, 2022; 12:724192; doi: 10.3389/fphar.2021.724192
62.
ParkCH, HahmER, LeeJH, et al.Ionomycin downregulates β-catenin/Tcf signaling in colon cancer cell line. Carcinogenesis, 2005; 26(11):1929–1933; doi: 10.1093/carcin/bgi145
63.
ReddyD, GhoshP, KumavathR. Strophanthidin attenuates MAPK, PI3K/AKT/MTOR, and Wnt/β-catenin signaling pathways in human cancers. Front Oncol, 2020a;9:1469; doi: 10.3389/fonc.2019.01469
64.
ReddyD, KumavathR, GhoshP, et al.Lanatoside C induces G2/M cell cycle arrest and suppresses cancer cell growth by attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/MTOR signaling pathways. Biomolecules, 2019; 9(12):792; doi: 10.3390/biom9120792
65.
ReddyD, KumavathR, TanTZ, et al.Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/MTOR signaling pathways in human cancers. Life Sci, 2020b;241:117147; doi: 10.1016/j.lfs.2019.117147
66.
SchaackD, WeigandMA, UhleF. Comparison of machine-learning methodologies for accurate diagnosis of sepsis using microarray gene expression data. PLoS One, 2021; 16(5):e0251800; doi: 10.1371/journal.pone.0251800
67.
SchneiderNFZ, CerellaC, LeeJY, et al.Cardiac glycoside glucoevatromonoside induces cancer type-specific cell death. Front Pharmacol, 2018; 9:70; doi: 10.3389/fphar.2018.00070
68.
SchneiderNFZ, CerellaC, SimõesCMO, et al.Anticancer and immunogenic properties of cardiac glycosides. Molecules, 2017; 22(11):1932; doi: 10.3390/molecules22111932
69.
SchneiderNFZ, MenegazD, DagostinALA, et al.Cytotoxicity of glucoevatromonoside alone and in combination with chemotherapy drugs and their effects on Na+, K+-ATPase and ion channels on lung cancer cells. Mol Cell Biochem, 2021; 476(4):1825–1848; doi: 10.1007/s11010-020-04040-x
70.
Schrödinger, LLC. PyMOL. Version 2.5.7. 2023 Available from: https://pymol.org/2/
71.
SeguinL, DurandyM, FeralCC. Lung adenocarcinoma tumor origin: A guide for personalized medicine. Cancers (Basel), 2022; 14(7):1759; doi: 10.3390/cancers14071759
72.
ShimamuraT, ShapiroGI. Heat shock protein 90 inhibition in lung cancer. J Thorac Oncol, 2008; 3(6 Suppl 2):S152–S159; doi: 10.1097/JTO.0b013e318174ea3a
73.
SmythGK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol, 2004; 3:Article3; doi: 10.2202/1544-6115.1027
74.
SolomonJP, LinkovI, RosadoA, et al.NTRK fusion detection across multiple assays and 33,997 cases: Diagnostic implications and pitfalls. Mod Pathol, 2020; 33(1):38–46; doi: 10.1038/s41379-019-0324-7
75.
SubramanianA, NarayanR, CorselloSM, et al.A next generation connectivity map: L1000 platform and the first 1,000,000 Profiles. Cell, 2017; 171(6):1437–1452.e17; doi: 10.1016/j.cell.2017.10.049
76.
SunTH, WangCC, WuYL, et al.Machine learning approaches for biomarker discovery to predict large-artery atherosclerosis. Sci Rep, 2023; 13(1):15139; doi: 10.1038/s41598-023-42338-0
77.
SunGZ, ZhaoTW. Lung adenocarcinoma pathology stages related gene identification. Math Biosci Eng, 2019; 17(1):737–746; doi: 10.3934/mbe.2020038
78.
SuszynskaM, RatajskaM, KozlowskiP. BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: Mutation prevalence and precise risk estimates based on a pooled analysis of ∼30,000 cases. J Ovarian Res, 2020; 13(1):50; doi: 10.1186/s13048-020-00654-3
79.
TablAA, AlkhateebA, ElMaraghyW, et al.A machine learning approach for identifying gene biomarkers guiding the treatment of breast cancer. Front Genet, 2019; 10:256; doi: 10.3389/fgene.2019.00256
80.
TangZ, KangB, LiC, et al.GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res, 2019; 47(W1):W556–W560; doi: 10.1093/nar/gkz430
81.
TayJK, NarasimhanB, HastieT. Elastic net regularization paths for all generalized linear models. J Stat Softw, 2023; 106:1; doi: 10.18637/jss.v106.i01
82.
Team RC. A language and environment for statistical computing. R Foundation for Statistical Computing. 2018; Available from: https://www.R-project.org.
83.
TibshiraniR. Regression shrinkage and selection via the lasso. J R Stat Soc B, 1996; 58(1):267–288; doi: 10.1111/j.2517-6161.1996.tb02080.x
84.
TomczakK, CzerwińskaP, WiznerowiczM. The cancer genome atlas (TCGA): An immeasurable source of knowledge. Contemp Oncol (Pozn), 2015; 19(1A):A68–A77; doi: 10.5114/wo.2014.47136
85.
TrottO, OlsonAJ. AutoDock vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem, 2010; 31(2):455–461; doi: 10.1002/jcc.21334
86.
Van Der SteenN, ZwaenepoelK, MazzaschiG, et al.The role of C-met as a biomarker and player in innate and acquired resistance in non-small-cell lung cancer: Two new mutations warrant further studies. Molecules, 2019; 24(24):4443; doi: 10.3390/molecules24244443
87.
VolkamerA, KuhnD, RippmannF, et al.DoGSiteScorer: A web server for automatic binding site prediction, analysis and druggability assessment. Bioinformatics, 2012; 28(15):2074–2075; doi: 10.1093/bioinformatics/bts310
88.
WangS, FangX, WenX, et al.Prioritization of risk genes for alzheimer’s disease: An analysis framework using spatial and temporal gene expression data in the human brain based on support vector machine. Front Genet, 2023b;14:1190863; doi: 10.3389/fgene.2023.1190863
89.
WangZ, HeE, SaniK, et al.Drug Gene Budger (DGB): An application for ranking drugs to modulate a specific gene based on transcriptomic signatures. Bioinformatics, 2019; 35(7):1247–1248; doi: 10.1093/bioinformatics/bty763
90.
WangZ, LachmannA, KeenanAB, et al.L1000FWD: Fireworks visualization of drug-induced transcriptomic signatures. Bioinformatics, 2018; 34(12):2150–2152; doi: 10.1093/bioinformatics/bty060
91.
WangQ, LiL, QuT, et al.High expression of ACE2 and TMPRSS2 at the resection margin makes lung cancer survivors susceptible to SARS-CoV-2 with unfavorable prognosis. Front Oncol, 2021; 11:644575; doi: 10.3389/fonc.2021.644575
92.
WangF, SuQ, LiC. Identidication of novel biomarkers in non-small cell lung cancer using machine learning. Sci Rep, 2022; 12(1):16693; doi: 10.1038/s41598-022-21050-5
93.
WangLH, XuM, FuLQ, et al.The antihelminthic niclosamide inhibits cancer stemness, extracellular matrix remodeling, and metastasis through dysregulation of the nuclear β-catenin/c-Myc Axis in OSCC. Sci Rep, 2018; 8(1):12776; doi: 10.1038/s41598-018-30692-3
94.
WangR, ZhangJ, CuiX, et al.Multimolecular characteristics and role of BRCA1 interacting protein C-terminal helicase 1 (BRIP1) in human tumors: A pan-cancer analysis. World J Surg Oncol, 2023a;21(1):91; doi: 10.1186/s12957-022-02877-8
95.
Weber-LassalleN, HaukeJ, RamserJ, et al.BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. Breast Cancer Res, 2018; 20(1):7; doi: 10.1186/s13058-018-0935-9
96.
WishartDS, FeunangYD, GuoAC, et al.DrugBank 5.0: A major update to the drugbank database for 2018. Nucleic Acids Res, 2018; 46(D1):D1074–D1082; doi: 10.1093/nar/gkx1037
97.
XueQ, LiuZ, FengZ, et al.Penfluridol: An antipsychotic agent suppresses lung cancer cell growth and metastasis by inducing G0/G1 arrest and apoptosis. Biomed Pharmacother, 2020; 121:109598; doi: 10.1016/j.biopha.2019.109598
98.
YehCT, WuAT, ChangPM, et al.Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am J Respir Crit Care Med, 2012; 186(11):1180–1188; doi: 10.1164/rccm.201207-1180OC
99.
YuanM, HuangLL, ChenJH, et al.The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther, 2019; 4:61; doi: 10.1038/s41392-019-0099-9
100.
ZhangR, LiuP, ZhangX, et al.Lin28A promotes the proliferation and stemness of lung cancer cells via the activation of mitogen-activated protein kinase pathway dependent on microrna Let-7c. Ann Transl Med, 2021; 9(12):982; doi: 10.21037/atm-21-2124
101.
ZhaoS, BaoZ, ZhaoX, et al.Identification of diagnostic markers for major depressive disorder using machine learning methods. Front Neurosci, 2021; 15:645998; doi: 10.3389/fnins.2021.645998
102.
ZhaoD, WangL, ChenZ, et al.KRAS is a prognostic biomarker associated with diagnosis and treatment in multiple cancers. Front Genet, 2022; 13:1024920; doi: 10.3389/fgene.2022.1024920
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
